Sarepta Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
SRPT$16.42-4.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands)
| Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||||
| Common Stock Issued · Treasury Stock · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||||
| Shares | Amount | Shares | Amount | Capital | (Loss) Income | Deficit | Equity | |
| BALANCE AT DECEMBER 31, 2022 | 87,950 | $9 | — | $— | $4,296,841 | $(1,664) | $(3,910,236) | $384,950 |
| Exercise of options for common stock | 528 | — | — | — | 40,485 | — | — | 40,485 |
| Vest of restricted stock units | 645 | — | — | — | — | — | — | — |
| Issuance of common stock for exchange of 2024 Notes | 4,456 | — | — | — | 693,377 | — | — | 693,377 |
| Partial settlement of capped call share options for 2024 Notes | — | — | — | — | 80,645 | — | — | 80,645 |
| Issuance of common stock under employee stock purchase plan | 153 | — | — | — | 10,761 | — | — | 10,761 |
| Stock-based compensation | — | — | — | — | 182,514 | — | — | 182,514 |
| Unrealized gains from investments, net of tax | — | — | — | — | — | 2,582 | — | 2,582 |
| Net loss | — | — | — | — | — | — | (535,977) | (535,977) |
| BALANCE AT DECEMBER 31, 2023 | 93,732 | 9 | — | — | 5,304,623 | 918 | (4,446,213) | 859,337 |
| Exercise of options for common stock | 850 | 1 | — | — | 67,319 | — | — | 67,320 |
| Vest of restricted stock units | 734 | — | — | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 143 | — | — | — | 12,205 | — | — | 12,205 |
| Issuance of common stock for conversion of 2024 Notes | 1,441 | — | — | — | 105,757 | — | — | 105,757 |
| Modification of 2017 Capped Calls | — | — | — | — | 43,887 | — | — | 43,887 |
| Stock-based compensation | — | — | — | — | 205,133 | — | — | 205,133 |
| Unrealized losses from investments, net of tax | — | — | — | — | — | (1,136) | — | (1,136) |
| Net income | — | — | — | — | — | — | 235,239 | 235,239 |
| BALANCE AT DECEMBER 31, 2024 | 96,900 | 10 | — | — | 5,738,924 | (218) | (4,210,974) | 1,527,742 |
| Cumulative effect of accounting change to adopt ASU 2025-07 (defined in Note 2) | — | — | — | — | — | — | 47,400 | 47,400 |
| Exercise of options for common stock | 223 | — | — | — | 10,870 | — | — | 10,870 |
| Vest of restricted stock units | 1,237 | — | — | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 150 | — | — | — | 7,833 | — | — | 7,833 |
| Repurchases of common stock | — | — | (651) | (25,263) | — | — | — | (25,263) |
| Issuance of common stock for the Exchange Transactions (defined in Note 13), net of issuance costs | 5,851 | 1 | — | — | 104,934 | — | — | 104,935 |
| Incremental option value associated with the December 2025 Exchange (defined in Note 13) | — | — | — | — | 21,082 | — | — | 21,082 |
| Issuance of common stock | 1,107 | — | — | — | 20,000 | — | — | 20,000 |
| Issuance of performance stock awards | 147 | — | — | — | — | — | — | — |
| Restructuring charge | — | — | — | — | (134) | — | — | (134) |
| Stock-based compensation | — | — | — | — | 139,077 | — | — | 139,077 |
| Unrealized gains from investments, net of tax | — | — | — | — | — | 490 | — | 490 |
| Net loss | — | — | — | — | — | — | (713,410) | (713,410) |
| BALANCE AT DECEMBER 31, 2025 | 105,615 | $11 | (651) | $(25,263) | $6,042,586 | $272 | $(4,876,984) | $1,140,622 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.